Nuo Therapeutics, Inc. financial data

Symbol
AURX on OTC
Industry
Surgical & Medical Instruments & Apparatus
Location
8285 El Rio, Suite 150, Houston, TX
State of incorporation
DE
Fiscal year end
December 31
Former names
CYTOMEDIX INC (to 10/8/2014), AUTOLOGOUS WOUND THERAPY INC (to 4/10/2000), AUTOLOGOUS WOUND TRERAPY INC (to 3/23/2000)
Latest financial report
10-K - Q4 2024 - Apr 1, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 158 % -24.3%
Quick Ratio 27.2 % -13.9%
Debt-to-equity 139 % +41.1%
Return On Equity -398 % -12.1%
Return On Assets -167 % +6.85%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 46.8M shares +5.82%
Common Stock, Shares, Outstanding 46.8M shares +5.82%
Entity Public Float 10M USD -72.1%
Common Stock, Value, Issued 4.68K USD +5.83%
Weighted Average Number of Shares Outstanding, Basic 45.4M shares +7.95%

Income Statement

Label TTM Value / Value Unit Change %
Operating Income (Loss) -2.46M USD +22.4%
Nonoperating Income (Expense) -794 USD +27%
Net Income (Loss) Attributable to Parent -2.32M USD +26.7%
Earnings Per Share, Basic -0.05 USD/shares +37.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 284K USD -69.5%
Accounts Receivable, after Allowance for Credit Loss, Current 248K USD -1%
Inventory, Net 150K USD -28.2%
Assets, Current 842K USD -46.2%
Property, Plant and Equipment, Net 177K USD +293%
Operating Lease, Right-of-Use Asset 171K USD -36.5%
Assets 1.19M USD -36.7%
Accounts Payable, Current 219K USD -44.4%
Accrued Liabilities, Current 292K USD +55%
Liabilities, Current 578K USD -14.2%
Operating Lease, Liability, Noncurrent 97.3K USD -40.7%
Liabilities 676K USD -19.4%
Retained Earnings (Accumulated Deficit) -32.3M USD -7.76%
Stockholders' Equity Attributable to Parent 514K USD -50.6%
Liabilities and Equity 1.19M USD -36.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -562K USD +29.3%
Net Cash Provided by (Used in) Financing Activities 0 USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 46.8M shares +5.82%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -562K USD +29.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 300K USD -67.7%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1.21K USD +63.7%
Deferred Tax Assets, Valuation Allowance 40.7M USD -1.25%
Deferred Tax Assets, Gross 40.7M USD -1.25%
Operating Lease, Liability 164K USD -35.8%
Depreciation 23K USD +50.2%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid 184K USD -38%
Property, Plant and Equipment, Gross 610K USD +34.1%
Operating Lease, Liability, Current 66.9K USD -26.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 82.7K USD +3.03%
Lessee, Operating Lease, Liability, to be Paid, Year One 80.3K USD -28.9%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 20.1K USD -51.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 21.3K USD -74.3%
Deferred Tax Assets, Operating Loss Carryforwards 40.5M USD -1.13%
Preferred Stock, Shares Authorized 1M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 21.3K USD -74.3%
Additional Paid in Capital 32.8M USD +5.81%
Share-based Payment Arrangement, Expense 56.7K USD +161%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%